Nrdp 1-Mediated Regulation of ErbB 3 Expression by the Androgen Receptor in Androgen-Dependent but not Castrate-Resistant Prostate Cancer Cells

Authors' A Mather, Ca Sacrament San Anto Translatio Michigan M Note: Sup Research O Correspon University 3500, Sacra E-mail: Par

[1]  P. Abrahamsson,et al.  Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. , 2010, European urology.

[2]  A. Chinnaiyan,et al.  Nuclear versus Cytoplasmic Localization of Filamin A in Prostate Cancer: Immunohistochemical Correlation with Metastases , 2009, Clinical Cancer Research.

[3]  Y. Wang,et al.  Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival , 2008, Oncogene.

[4]  J. Kreisberg,et al.  AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer. , 2008, Advances in experimental medicine and biology.

[5]  Y. Wang,et al.  A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells , 2007, Oncogene.

[6]  J. Diallo,et al.  Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer , 2007, BJU international.

[7]  C. Tepper,et al.  The oncogenic potential of a prostate cancer‐derived androgen receptor mutant , 2007, The Prostate.

[8]  Kermit L. Carraway,et al.  Neuregulin-Induced ErbB3 Downregulation Is Mediated by a Protein Stability Cascade Involving the E3 Ubiquitin Ligase Nrdp1 , 2007, Molecular and Cellular Biology.

[9]  Xiuli Wu,et al.  Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. , 2006, Cancer research.

[10]  W. Hahn,et al.  Androgen-dependent regulation of Her-2/neu in prostate cancer cells. , 2006, Cancer research.

[11]  C. D. de Ridder,et al.  Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. , 2006, The Journal of nutrition.

[12]  I. H. Koumakpayi,et al.  Expression and Nuclear Localization of ErbB3 in Prostate Cancer , 2006, Clinical Cancer Research.

[13]  J. Terwilliger,et al.  Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. , 2006, Carcinogenesis.

[14]  A. Hamburger,et al.  The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Troyer,et al.  Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. , 2005, Endocrine-related cancer.

[16]  F. S. French,et al.  Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth , 2005, Clinical Cancer Research.

[17]  A. Hamburger,et al.  Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling , 2004, British Journal of Cancer.

[18]  D. Ghosh,et al.  Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.

[19]  Ingo K Mellinghoff,et al.  HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.

[20]  Xiuli Wu,et al.  Stabilization of the E3 Ubiquitin Ligase Nrdp1 by the Deubiquitinating Enzyme USP8 , 2004, Molecular and Cellular Biology.

[21]  E. Schwartz.  1989 American Association for Cancer Research , 1989, Journal of Cancer Research and Clinical Oncology.

[22]  C. Tepper,et al.  Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. , 2002, Cancer research.

[23]  A. Goldberg,et al.  Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Carraway,et al.  An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Oxley,et al.  Her-2/neu oncogene amplification in clinically localised prostate cancer. , 2002, Journal of clinical pathology.

[26]  W. Muller,et al.  Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins* , 2001, The Journal of Biological Chemistry.

[27]  C. Cordon-Cardo,et al.  HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  M. Sliwkowski,et al.  A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. , 2001, Cancer research.

[29]  W. Gullick,et al.  Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3. , 2001, Cellular signalling.

[30]  M. Rubin,et al.  Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. , 2001, Neoplasia.

[31]  K. Makino,et al.  HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. , 2000, Cancer research.

[32]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[33]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[34]  Y. Yarden,et al.  Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. , 2000, Cancer research.

[35]  M. Hung,et al.  HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* , 2000, The Journal of Biological Chemistry.

[36]  K. Pienta,et al.  Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  C. Cordon-Cardo,et al.  Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. , 1999, Journal of the National Cancer Institute.

[38]  R. Adam,et al.  The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. , 1999, Cancer research.

[39]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Trapman,et al.  Mechanisms of androgen receptor activation and function , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[41]  J. Koland,et al.  Mutation of a Shc Binding Site Tyrosine Residue in ErbB3/HER3 Blocks Heregulin-dependent Activation of Mitogen-activated Protein Kinase* , 1998, The Journal of Biological Chemistry.

[42]  H. Kung,et al.  Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells , 1998, Nature.

[43]  J. Rhim,et al.  ErbB kinases and NDF signaling in human prostate cancer cells , 1997, Oncogene.

[44]  M. Melhem,et al.  Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. , 1997, The cancer journal from Scientific American.

[45]  W. Grizzle,et al.  Elevated serum levels of p105erbB‐2 in patients with advanced‐stage prostatic adenocarcinoma , 1996, International journal of cancer.

[46]  T. H. van der Kwast,et al.  Development of seven new human prostate tumor xenograft models and their histopathological characterization. , 1996, The American journal of pathology.

[47]  S. Schwartz,et al.  CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. , 1996, Cancer research.

[48]  H. Kung,et al.  A tyrosine kinase profile of prostate carcinoma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. Gleave,et al.  Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. , 1993, Cancer research.